On July 1, 2024 Vivesto AB, an oncology-focused research and development company, reported that new positive preclinical efficacy data was obtained further supporting the continued development of the candidate drug Cantrixil for hematological cancer (Press release, Vivesto, JUL 1, 2024, View Source [SID1234644628]). The new in vitro data in hematological cancer cell lines show clear positive effects in combination with other anti-cancer drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The results obtained provide essential information about the action of Cantrixil in combination with other anti-cancer drugs and gives good guidance in the continued preclinical evaluation and moving of the program towards clinical studies in hard-to-treat hematological cancer indications. An understanding of the effects of combinations is important since Cantrixil, as almost all other new cancer therapies, would be developed in the clinic and initially used when marketed in combination with other anti-cancer agents," said Erik Kinnman, CEO of Vivesto.

The new preclinical data further strengthens previous positive results with Cantrixil, which has shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancers. Furthermore, the data provide guidance to upcoming in vivo experiments, as well as towards clinical development. Specifically, the data adds input to the dosing selection and regime in the planning of the next set of experiments, which will include in vivo hematological cancer models and patient sample testing.